| Currently, because globalization, the pharmaceutical industry is facing
enormous challenges to comply with regulatory matters. Reduced patent
life and overall decreased profitability of newly discovered drugs are also
forcing the pharmaceutical industry to shorten the drug development
time with maximum throughput. Therefore, continuous manufacturing
(CM) processes via hot melt extrusion (HME) can be a promising
alternative for achieving these goals. HME offers solvent-free green
technology with a process that is easy to scale up. Moreover, CM provides
better product quality assurance compared with batch processes, with
fewer labor costs and shorter time to development. In this review, we
primarily focus on various aspects of CM and the emerging application of
HME to bridge the current manufacturing gap in pharmaceutical sphere. |